Current Protein Identity:A4TVL0 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
4V2Y Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide Deposited 2014-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M MAGNESIUM CHLORIDE, 0.1 M SODIUM CITRATE PH 5, 15%(W/V) PEG 4000
Resolution 1.40 Å R-free 0.195
4V2Y Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide Deposited 2014-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M MAGNESIUM CHLORIDE, 0.1 M SODIUM CITRATE PH 5, 15%(W/V) PEG 4000
Resolution 1.40 Å R-free 0.195
4V2Y Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide Deposited 2014-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M MAGNESIUM CHLORIDE, 0.1 M SODIUM CITRATE PH 5, 15%(W/V) PEG 4000
Resolution 1.40 Å R-free 0.195
4V2Z Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide Deposited 2014-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 Y70 S-Pomalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M SODIUM ACETATE PH 4.6, 15 %(W/V) PEG 20000
Resolution 1.45 Å R-free 0.203
4V2Z Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide Deposited 2014-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 Y70 S-Pomalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M SODIUM ACETATE PH 4.6, 15 %(W/V) PEG 20000
Resolution 1.45 Å R-free 0.203
4V2Z Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pomalidomide Deposited 2014-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 Y70 S-Pomalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M SODIUM ACETATE PH 4.6, 15 %(W/V) PEG 20000
Resolution 1.45 Å R-free 0.203
4V30 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide Deposited 2014-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 LVY S-Lenalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 15 %(W/V) PEG 6000, 5 %(W/V) GLYCEROL
Resolution 1.85 Å R-free 0.239
4V30 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide Deposited 2014-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 LVY S-Lenalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 15 %(W/V) PEG 6000, 5 %(W/V) GLYCEROL
Resolution 1.85 Å R-free 0.239
4V30 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Lenalidomide Deposited 2014-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 LVY S-Lenalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 15 %(W/V) PEG 6000, 5 %(W/V) GLYCEROL
Resolution 1.85 Å R-free 0.239
4V31 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine Deposited 2014-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 DUR 2'-DEOXYURIDINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M CITRIC ACID PH 3.5, 25 %(W/V) PEG 3350
Resolution 1.80 Å R-free 0.219
4V31 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine Deposited 2014-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 DUR 2'-DEOXYURIDINE × 1 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M CITRIC ACID PH 3.5, 25 %(W/V) PEG 3350
Resolution 1.80 Å R-free 0.219
4V31 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Deoxyuridine Deposited 2014-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 DUR 2'-DEOXYURIDINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.1 M CITRIC ACID PH 3.5, 25 %(W/V) PEG 3350
Resolution 1.80 Å R-free 0.219
4V32 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant Deposited 2014-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Mutation:YES ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.2 M SODIUM CHLORIDE, 0.1 M PHOSPHATE-CITRATE PH 4.2, 20 %(W/V) PEG 8000
Resolution 1.90 Å R-free 0.240
4V32 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant Deposited 2014-10-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Mutation:YES ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.2 M SODIUM CHLORIDE, 0.1 M PHOSPHATE-CITRATE PH 4.2, 20 %(W/V) PEG 8000
Resolution 1.90 Å R-free 0.240
4V32 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Y101F mutant Deposited 2014-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Mutation:YES ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 0.2 M SODIUM CHLORIDE, 0.1 M PHOSPHATE-CITRATE PH 4.2, 20 %(W/V) PEG 8000
Resolution 1.90 Å R-free 0.240
5AMH Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, trigonal crystal form Deposited 2015-03-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 CA CALCIUM ION × 1 CL CHLORIDE ION × 7 NI NICKEL (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM SODIUM ACETATE PH 4.6, 2.2 M CALCIUM CHLORIDE
Resolution 1.20 Å R-free 0.157
5AMI Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure Deposited 2015-03-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM SODIUM ACETATE PH 4.6, 20 %(W/V) PEG 6000
Resolution 1.75 Å R-free 0.209
5AMI Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure Deposited 2015-03-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM SODIUM ACETATE PH 4.6, 20 %(W/V) PEG 6000
Resolution 1.75 Å R-free 0.209
5AMI Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash I structure Deposited 2015-03-10 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM SODIUM ACETATE PH 4.6, 20 %(W/V) PEG 6000
Resolution 1.75 Å R-free 0.209
5AMJ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure Deposited 2015-03-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM TRI-SODIUM CITRATE PH 5.6, 1.0 M AMMONIUM PHOSPHATE
Resolution 1.75 Å R-free 0.191
5AMJ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure Deposited 2015-03-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM TRI-SODIUM CITRATE PH 5.6, 1.0 M AMMONIUM PHOSPHATE
Resolution 1.75 Å R-free 0.191
5AMJ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thalidomide, Wash II structure Deposited 2015-03-10 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 100 MM TRI-SODIUM CITRATE PH 5.6, 1.0 M AMMONIUM PHOSPHATE
Resolution 1.75 Å R-free 0.191
5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form Deposited 2015-03-10 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
Resolution 2.90 Å R-free 0.217
5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form Deposited 2015-03-10 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
Resolution 2.90 Å R-free 0.217
5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form Deposited 2015-03-10 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
Resolution 2.90 Å R-free 0.217
5AMK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in multiple conformations, hexagonal crystal form Deposited 2015-03-10 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 64 MM SODIUM CITRATE PH 7.0, 100 MM HEPES PH 7.0, 10 %(W/V) PEG 5000 MME
Resolution 2.90 Å R-free 0.217
5OH1 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate PH 4.6, 15 %(W/V) PEG 20000
Resolution 1.70 Å R-free 0.210
5OH1 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate PH 4.6, 15 %(W/V) PEG 20000
Resolution 1.70 Å R-free 0.210
5OH1 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Aminoglutethimide Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UQ (3~{R})-3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate PH 4.6, 15 %(W/V) PEG 20000
Resolution 1.70 Å R-free 0.210
5OH2 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam) Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 BAQ pyrrolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.90 Å R-free 0.225
5OH2 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam) Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 BAQ pyrrolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.90 Å R-free 0.225
5OH2 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Pyrrolidin-2-one (Butyrolactam) Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 BAQ pyrrolidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.90 Å R-free 0.225
5OH3 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9V2 (3~{S})-3-ethyl-3-methyl-pyrrolidine-2,5-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 2.10 Å R-free 0.231
5OH3 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9V2 (3~{S})-3-ethyl-3-methyl-pyrrolidine-2,5-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 2.10 Å R-free 0.231
5OH3 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Ethosuximide Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 2.10 Å R-free 0.231
5OH4 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide) Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UZ piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 2.30 Å R-free 0.250
5OH4 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide) Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UZ piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 2.30 Å R-free 0.250
5OH4 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidine-2,6-dione (Glutarimide) Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UZ piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 2.30 Å R-free 0.250
5OH7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin) Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 HYN imidazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.85 Å R-free 0.203
5OH7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin) Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 HYN imidazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.85 Å R-free 0.203
5OH7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Imidazolidine-2,4-dione (Hydantoin) Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.85 Å R-free 0.203
5OH8 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 ROL ROLIPRAM × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.95 Å R-free 0.220
5OH8 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 ROL ROLIPRAM × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.95 Å R-free 0.220
5OH8 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Rolipram Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.95 Å R-free 0.220
5OH9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 OD3 1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.65 Å R-free 0.210
5OH9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 OD3 1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.65 Å R-free 0.210
5OH9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Thiazolidine-2,4-dione Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 OD3 1,3-thiazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.65 Å R-free 0.210
5OHA Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UW 2-sulfanylideneimidazol-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.55 Å R-free 0.197
5OHA Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UW 2-sulfanylideneimidazol-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.55 Å R-free 0.197
5OHA Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with 2-Thiohydantoin Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9UW 2-sulfanylideneimidazol-4-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.55 Å R-free 0.197
5OHB Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam) Deposited 2017-07-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 V1L piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.70 Å R-free 0.212
5OHB Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam) Deposited 2017-07-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 V1L piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.70 Å R-free 0.212
5OHB Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Piperidin-2-one (Valerolactam) Deposited 2017-07-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 V1L piperidin-2-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.1 M sodium acetate pH 4.6, 15 %(W/V) PEG 20000
Resolution 1.70 Å R-free 0.212
6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide Deposited 2019-03-13 Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 1–124(124 aa)
Mutation:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
Resolution 1.50 Å R-free 0.190
6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide Deposited 2019-03-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Mutation:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
Resolution 1.50 Å R-free 0.190
6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide Deposited 2019-03-13 Assembly 3 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain C 1–124(124 aa)
Mutation:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
Resolution 1.50 Å R-free 0.190
6R0Q Mutant cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with thalidomide metabolite alpha-(o-carboxybenzamido)glutarimide Deposited 2019-03-13 Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain D 1–124(124 aa)
Mutation:A52H, M54Y, F56H, R68N, A72R, I87V, L89Q ZN ZINC ION × 1 JNW 2-[[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamoyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;20 % PEG 3350, 0.2 M Ammonium acetate
Resolution 1.50 Å R-free 0.190
6R0S Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product Deposited 2019-03-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.55 Å R-free 0.213
6R0S Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product Deposited 2019-03-13 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOE 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-6-nitro-benzoic acid × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.55 Å R-free 0.213
6R0S Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 4a and hydrolysis product Deposited 2019-03-13 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JOH 2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-4-nitro-isoindole-1,3-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.55 Å R-free 0.213
6R0U Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product Deposited 2019-03-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.70 Å R-free 0.227
6R0U Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product Deposited 2019-03-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 JO8 3-azanyl-2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]benzoic acid × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.70 Å R-free 0.227
6R0U Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5a and hydrolysis product Deposited 2019-03-13 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JO5 4-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.70 Å R-free 0.227
6R0V Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b Deposited 2019-03-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JO2 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-4-nitro-benzoic acid × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.60 Å R-free 0.219
6R0V Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b Deposited 2019-03-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JO2 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-4-nitro-benzoic acid × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.60 Å R-free 0.219
6R0V Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b Deposited 2019-03-13 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JO2 2-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyl]-4-nitro-benzoic acid × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.60 Å R-free 0.219
6R11 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b Deposited 2019-03-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JOB 5-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
Resolution 1.75 Å R-free 0.227
6R11 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b Deposited 2019-03-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JOB 5-azanyl-2-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]isoindole-1,3-dione × 1 PO4 PHOSPHATE ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
Resolution 1.75 Å R-free 0.227
6R11 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 5b Deposited 2019-03-13 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
Resolution 1.75 Å R-free 0.227
6R12 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b Deposited 2019-03-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.74 Å R-free 0.234
6R12 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b Deposited 2019-03-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOT ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2-phenyl-ethanamide × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.74 Å R-free 0.234
6R12 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7b Deposited 2019-03-13 Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.74 Å R-free 0.234
6R13 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f Deposited 2019-03-13 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.65 Å R-free 0.224
6R13 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f Deposited 2019-03-13 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOK ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-3-phenyl-propanamide × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.65 Å R-free 0.224
6R13 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7f Deposited 2019-03-13 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.65 Å R-free 0.224
6R18 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a Deposited 2019-03-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.35 Å R-free 0.197
6R18 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a Deposited 2019-03-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JOQ [4-(aminomethyl)phenyl]methyl ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.35 Å R-free 0.197
6R18 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 11a Deposited 2019-03-14 Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.35 Å R-free 0.197
6R19 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a Deposited 2019-03-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.45 Å R-free 0.201
6R19 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a Deposited 2019-03-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 JON [(2~{S})-pyrrolidin-2-yl]methyl ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.45 Å R-free 0.201
6R19 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a Deposited 2019-03-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.45 Å R-free 0.201
6R1A Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b Deposited 2019-03-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 m Ammonium phosphate
Resolution 1.54 Å R-free 0.208
6R1A Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b Deposited 2019-03-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 m Ammonium phosphate
Resolution 1.54 Å R-free 0.208
6R1A Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20b Deposited 2019-03-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JP8 [(2~{R})-pyrrolidin-2-yl]methyl ~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 m Ammonium phosphate
Resolution 1.54 Å R-free 0.208
6R1C Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a Deposited 2019-03-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ASP ASPARTIC ACID × 1 ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.50 Å R-free 0.215
6R1C Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a Deposited 2019-03-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 JOW 4-[[4-[[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamoyloxymethyl]phenyl]methylamino]-4-oxidanylidene-butanoic acid × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.50 Å R-free 0.215
6R1C Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 12a Deposited 2019-03-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.50 Å R-free 0.215
6R1D Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7d, co-crystallized Deposited 2019-03-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JP5 (phenylmethyl) ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;15 % PEG 6K, 5 % Glycerol
Resolution 1.10 Å R-free 0.150
6R1D Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7d, co-crystallized Deposited 2019-03-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JP5 (phenylmethyl) ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;15 % PEG 6K, 5 % Glycerol
Resolution 1.10 Å R-free 0.150
6R1K Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c Deposited 2019-03-14 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JPB ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2,4,6-tris(chloranyl)benzamide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.94 Å R-free 0.212
6R1K Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c Deposited 2019-03-14 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JPB ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2,4,6-tris(chloranyl)benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.94 Å R-free 0.212
6R1K Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7c Deposited 2019-03-14 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JPB ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-2,4,6-tris(chloranyl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.94 Å R-free 0.212
6R1W Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b Deposited 2019-03-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
Resolution 1.35 Å R-free 0.198
6R1W Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b Deposited 2019-03-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 JPW (4-azanylcyclohexyl)methyl ~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
Resolution 1.35 Å R-free 0.198
6R1W Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 16b Deposited 2019-03-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 JPW (4-azanylcyclohexyl)methyl ~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]carbamate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium Phosphate
Resolution 1.35 Å R-free 0.198
6R1X Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a Deposited 2019-03-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JPQ ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-3-methyl-but-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.80 Å R-free 0.216
6R1X Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a Deposited 2019-03-15 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 JPQ ~{N}-[(3~{S})-2,5-bis(oxidanylidene)pyrrolidin-3-yl]-3-methyl-but-2-enamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.80 Å R-free 0.216
6R1X Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 7a Deposited 2019-03-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.4 M Ammonium phosphate
Resolution 1.80 Å R-free 0.216
7PJK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide Deposited 2021-08-24 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 7SE (3S)-3-(benzotriazol-2-yl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.4 M (NH4)2HPO4
Resolution 1.99 Å R-free 0.254
7PJK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide Deposited 2021-08-24 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 7SE (3S)-3-(benzotriazol-2-yl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.4 M (NH4)2HPO4
Resolution 1.99 Å R-free 0.254
7PJK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with a benzotriazole analog of thalidomide Deposited 2021-08-24 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.4 M (NH4)2HPO4
Resolution 1.99 Å R-free 0.254
7PS9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220) Deposited 2021-09-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 8W7 (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
Resolution 1.80 Å R-free 0.246
7PS9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220) Deposited 2021-09-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 8W7 (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
Resolution 1.80 Å R-free 0.246
7PS9 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Iberdomide (CC-220) Deposited 2021-09-22 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 8W7 (3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
Resolution 1.80 Å R-free 0.246
7PSO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122) Deposited 2021-09-23 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
Resolution 1.52 Å R-free 0.217
7PSO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122) Deposited 2021-09-23 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
Resolution 1.52 Å R-free 0.217
7PSO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with Avadomide (CC-122) Deposited 2021-09-23 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 1 835 (3S)-3-(5-azanyl-2-methyl-4-oxidanylidene-quinazolin-3-yl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;0.5 M (NH4)H2PO4
Resolution 1.52 Å R-free 0.217
7SHH Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione Deposited 2021-10-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9FT (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.6;291 K;0. 1M sodium acetate and 16% PEG 6000
Resolution 1.90 Å R-free 0.216
7SHH Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione Deposited 2021-10-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9FT (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.6;291 K;0. 1M sodium acetate and 16% PEG 6000
Resolution 1.90 Å R-free 0.216
7SHH Bacterial cereblon homologue in complex with (R)-3-(4-methoxyphenyl)piperidine-2,6-dione Deposited 2021-10-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 9FT (3R)-3-(4-methoxyphenyl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 4.6;291 K;0. 1M sodium acetate and 16% PEG 6000
Resolution 1.90 Å R-free 0.216
8AOP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r Deposited 2022-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 MW6 (3S)-3-[(3-aminophenyl)sulfanylmethyl]piperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
Resolution 1.94 Å R-free 0.227
8AOP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r Deposited 2022-08-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 MW6 (3S)-3-[(3-aminophenyl)sulfanylmethyl]piperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
Resolution 1.94 Å R-free 0.227
8AOP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 14r Deposited 2022-08-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
Resolution 1.94 Å R-free 0.227
8AOQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a Deposited 2022-08-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 N8F (3~{S})-3-(phenylsulfonylmethyl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
Resolution 2.09 Å R-free 0.233
8AOQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a Deposited 2022-08-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 N8F (3~{S})-3-(phenylsulfonylmethyl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
Resolution 2.09 Å R-free 0.233
8AOQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with compound 20a Deposited 2022-08-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;294 K;0.4M Ammonium Phosphate
Resolution 2.09 Å R-free 0.233
8BC6 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide Deposited 2022-10-15 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
Resolution 1.72 Å R-free 0.223
8BC6 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide Deposited 2022-10-15 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
Resolution 1.72 Å R-free 0.223
8BC6 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aspartimide degron peptide Deposited 2022-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
Resolution 1.72 Å R-free 0.223
8BC7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide Deposited 2022-10-15 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
Resolution 1.72 Å R-free 0.211
8BC7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide Deposited 2022-10-15 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
Resolution 1.72 Å R-free 0.211
8BC7 Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex an aminoglutarimide degron peptide Deposited 2022-10-15 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 EF2 S-Thalidomide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;294 K;0.5 M (NH4)H2PO4
Resolution 1.72 Å R-free 0.211
8C3H Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide Deposited 2022-12-23 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;274 K;0.5 M (NH4)H2PO4
Resolution 1.71 Å R-free 0.210
8C3H Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide Deposited 2022-12-23 Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;274 K;0.5 M (NH4)H2PO4
Resolution 1.71 Å R-free 0.210
8C3H Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron peptide Deposited 2022-12-23 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;274 K;0.5 M (NH4)H2PO4
Resolution 1.71 Å R-free 0.210
8OU3 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 8d Deposited 2023-04-21 Assembly 1 Protein homooligomer Homooligomer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 1–124(124 aa)
Chain B 1–124(124 aa)
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 3 EF2 S-Thalidomide × 2 PO4 PHOSPHATE ION × 3 W1T 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-fluoranyl-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.47 Å R-free 0.238
8OU4 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a Deposited 2023-04-21 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 W2F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-chloranyl-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 2.25 Å R-free 0.269
8OU4 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a Deposited 2023-04-21 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 W2F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-chloranyl-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 2.25 Å R-free 0.269
8OU4 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11a Deposited 2023-04-21 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 2.25 Å R-free 0.269
8OU5 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11b Deposited 2023-04-21 Assembly 1 Protein homooligomer Homooligomer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 1–124(124 aa)
Chain B 1–124(124 aa)
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 3 W1X 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-(trifluoromethyl)benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 2.30 Å R-free 0.253
8OU6 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11c Deposited 2023-04-21 Assembly 1 Protein homooligomer Homooligomer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 20–123(104 aa)
Chain B 20–123(104 aa)
Chain C 20–123(104 aa)
Not recorded ZN ZINC ION × 3 W26 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methyl-benzamide × 2 PO4 PHOSPHATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.84 Å R-free 0.225
8OU7 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d Deposited 2023-04-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 W1F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methoxy-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.70 Å R-free 0.224
8OU7 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d Deposited 2023-04-22 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 W1F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methoxy-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.70 Å R-free 0.224
8OU7 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11d Deposited 2023-04-22 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 W1F 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-methoxy-benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.70 Å R-free 0.224
8OU9 Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11e Deposited 2023-04-22 Assembly 1 Protein homooligomer Homooligomer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 18–123(106 aa)
Chain B 18–123(106 aa)
Chain C 18–123(106 aa)
Not recorded ZN ZINC ION × 3 W1B 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2-oxidanyl-benzamide × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.75 Å R-free 0.224
8OUA Cereblon isoform 4 in complex with novel Benzamide-Type Cereblon Binder 11f Deposited 2023-04-22 Assembly 1 Protein homooligomer Homooligomer;Protein × 3 PDB declaration: trimeric(3) Consistent with protein count
Chain A 19–123(105 aa)
Chain B 19–123(105 aa)
Chain C 18–123(106 aa)
Not recorded ZN ZINC ION × 3 W0Z 4-azanyl-~{N}-[(3~{S})-2,6-bis(oxidanylidene)piperidin-3-yl]-2,5-bis(fluoranyl)-3-methoxy-benzamide × 2 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION;294 K;0.5 M (NH4)H2PO4
Resolution 1.85 Å R-free 0.238
8RDP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a Deposited 2023-12-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ7 (5~{S})-3-(2-chlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.76 Å R-free 0.230
8RDP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a Deposited 2023-12-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ7 (5~{S})-3-(2-chlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.76 Å R-free 0.230
8RDP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8a Deposited 2023-12-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ7 (5~{S})-3-(2-chlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.76 Å R-free 0.230
8RDQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b Deposited 2023-12-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 YQO (5S)-3-(2,4-dichlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 2.03 Å R-free 0.249
8RDQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b Deposited 2023-12-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 YQO (5S)-3-(2,4-dichlorophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 2.03 Å R-free 0.249
8RDQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8b Deposited 2023-12-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 2.03 Å R-free 0.249
8RDR Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g Deposited 2023-12-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ3 (5~{S})-3-(2-nitrophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.58 Å R-free 0.214
8RDR Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g Deposited 2023-12-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ3 (5~{S})-3-(2-nitrophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.58 Å R-free 0.214
8RDR Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8g Deposited 2023-12-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ3 (5~{S})-3-(2-nitrophenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.58 Å R-free 0.214
8RDS Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i Deposited 2023-12-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ6 (5~{S})-3-(2-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 2.00 Å R-free 0.253
8RDS Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i Deposited 2023-12-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ6 (5~{S})-3-(2-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 2.00 Å R-free 0.253
8RDS Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8i Deposited 2023-12-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 2.00 Å R-free 0.253
8RDT Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j Deposited 2023-12-08 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ2 (5~{S})-3-(2,3,4-trimethoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM Thalidomide
Resolution 1.95 Å R-free 0.242
8RDT Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j Deposited 2023-12-08 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1HZ2 (5~{S})-3-(2,3,4-trimethoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-8,10-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM Thalidomide
Resolution 1.95 Å R-free 0.242
8RDT Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with spiro-isoxazol based compound 8j Deposited 2023-12-08 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM Thalidomide
Resolution 1.95 Å R-free 0.242
9GJQ Crystal structure of humanised cereblon from Magnetospirillum gryphiswaldense bound by dihydrouracil-indole compound [1-(1H-indol-6-yl)dihydro-2,4(1H,3H)-pyrimidinedione]. Deposited 2024-08-22 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 18–124(107 aa)
Mutation:A52H, M54Y, F56H, F77H, Y101F, R117A A1IMN 1-(1H-indol-6-yl)-1,3-diazinane-2,4-dione × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;293 K;10 % PEG8000, 8 % ethylene glycol and 100 mM Na-HEPES buffer (pH 7.5)
Resolution 1.39 Å R-free 0.209
9HTK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2n Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IXA (3S)-3-phenylsulfanylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.49 Å R-free 0.210
9HTK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2n Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1I4R (3R)-3-phenylsulfanylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.49 Å R-free 0.210
9HTK Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2n Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IXA (3S)-3-phenylsulfanylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.49 Å R-free 0.210
9HTL Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2j Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW9 (3~{R})-3-phenoxypiperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.74 Å R-free 0.217
9HTL Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2j Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW9 (3~{R})-3-phenoxypiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.74 Å R-free 0.217
9HTL Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2j Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.74 Å R-free 0.217
9HTM Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2o Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW8 (3R)-3-phenylazanylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.85 Å R-free 0.237
9HTM Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2o Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW8 (3R)-3-phenylazanylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.85 Å R-free 0.237
9HTM Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2o Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1I4P (3S)-3-phenylazanylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.85 Å R-free 0.237
9HTN Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2s Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW7 (3R)-3-(3,4-dihydro-2H-quinolin-1-yl)piperidine-2,6-dione × 1 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.92 Å R-free 0.235
9HTN Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2s Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1I4Q (3S)-3-(3,4-dihydro-2H-quinolin-1-yl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.92 Å R-free 0.235
9HTN Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2s Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1I4Q (3S)-3-(3,4-dihydro-2H-quinolin-1-yl)piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.92 Å R-free 0.235
9HTO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2r Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW6 (3~{S})-3-indol-1-ylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.85 Å R-free 0.240
9HTO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2r Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW6 (3~{S})-3-indol-1-ylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.85 Å R-free 0.240
9HTO Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2r Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW6 (3~{S})-3-indol-1-ylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 1.85 Å R-free 0.240
9HTP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2p Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 2.35 Å R-free 0.281
9HTP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2p Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW5 (3~{S})-3-[methyl(phenyl)amino]piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 2.35 Å R-free 0.281
9HTP Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2p Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3mM thalidomide
Resolution 2.35 Å R-free 0.281
9HTQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2u Deposited 2024-12-19 Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW4 (3~{S})-3-carbazol-9-ylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.63 Å R-free 0.202
9HTQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2u Deposited 2024-12-19 Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain B 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW4 (3~{S})-3-carbazol-9-ylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.63 Å R-free 0.202
9HTQ Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex with glutarimide based compound 2u Deposited 2024-12-19 Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain C 1–124(124 aa)
Not recorded ZN ZINC ION × 1 A1IW4 (3~{S})-3-carbazol-9-ylpiperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;293 K;0.4-0.6 M (NH4)H2PO4, ~17 mg/ml MSCI4 with 3 mM thalidomide
Resolution 1.63 Å R-free 0.202